We report a 36-year-old woman in Iran who sought care for left shoulder pain and cough 5 days after a scheduled cesarean section. Acute pulmonary embolism and coronavirus disease were diagnosed. Physicians should be aware of the potential for these concurrent conditions in postpartum women.

An outbreak of viral pneumonia that emerged in late 2019 and spread rapidly worldwide was named coronavirus disease (COVID-19) (1). COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two other viruses of this family, severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, also have caused outbreaks globally (1). Venous embolism has been associated with severe infection. Acute pulmonary embolism has been associated with severe acute respiratory syndrome coronavirus infections, but no cases have been reported with Middle East respiratory syndrome (2,3). A study reported a 75-year-old hospitalized woman with COVID-19 and pulmonary embolism (4). In addition, in 2 COVID-19–positive patients, 57 and 70 years of age, from Wuhan, China, computed tomography angiography (CTA) confirmed pulmonary embolism (5). Three cases of deep vein thrombosis with COVID-19 also have been reported (6).

Pregnancy increases the risk for venous embolism (7). Although approximately half of venous embolism occurs during pregnancy and half occurs during the postpartum period, the risk per day is greatest in the weeks immediately after delivery (8). We report a patient in Iran who sought care for cough and shoulder pain 5 days after an uncomplicated cesarean delivery in whom an acute pulmonary embolism and COVID-19 infection were subsequently diagnosed. The ethics committee of Shiraz University of Medical Sciences (Shiraz, Iran) approved the study.

A healthy 36-year-old nonsmoking woman (gravida 2, 1 term infant delivered, 1 abortion/miscarriage) underwent an elective scheduled cesarean section at 37 weeks 2 days of gestation after an uncomplicated pregnancy. The uncomplicated surgery resulted in the birth of a healthy infant. Mechanical prophylaxis to prevent deep vein thrombosis was used at delivery until ambulation. The woman was discharged on postpartum day 2 in a good condition. On postpartum day 5, she sought care for sudden onset left-side shoulder pain and dry cough. She stated that she did not have fever, myalgia, or diarrhea. On postpartum day 5, she experienced mild shortness of breath. During her pregnancy, she had no known history of contact with persons who had confirmed or suspected COVID-19.

At admission, physical examination revealed a blood pressure of 110/70 mm Hg, body temperature of 36.8°C, pulse rate of 92 beats/min, respiratory rate of 20 breaths/min, and oxygen saturation of 94% on ambient air. Her body mass index was 24.8 kg/m^2. Her physical examination was otherwise unremarkable.

Laboratory test results showed a complete blood count and leukocyte differentials within reference ranges but elevated liver function tests, C-reactive...
protein level, and erythrocyte sedimentation rate. D-dimer was 800 μg/mL (reference <500 μg/mL). Results of her baseline electrocardiogram were unremarkable. She had a normal echocardiography with ejection fraction of ≈60%.

Because of the COVID-19 pandemic and the patient’s report of cough, she underwent screening for SARS-CoV-2. Throat swab samples were positive for SARS-CoV-2 by real-time reverse transcription PCR. Moreover, because of her clinical features, history, risk for venous embolism, and high level of D-dimer, CTA was performed. Thoracic CTA on the first day of hospitalization showed emboli in the right side interlobar artery, posterior basal segment, and the lingular branch (Figure, panels A, B). Hampton hump in the right side posterior basal segment was consistent with lung infarction. CTA further revealed left-sided pleural effusion associated with new mixed consolidation and ground glass opacifications (Figure, panels C, D).

CTA findings were consistent with pneumonia, pulmonary embolism, and lung infarction. The patient was treated with enoxaparin (1 mg/kg subcutaneously 2×/d). She was discharged in good condition with enoxaparin for 6 months.

Multiple conditions made this patient susceptible to pulmonary embolism. Because inflammation and coagulation are related, infected patients have hypercoagulable state (2). Virchow’s triad, which contributes to thrombosis, has 3 factors: venous stasis, hypercoagulability, and endothelial injury. Septic patients have criteria of Virchow’s triad; cesarean section as a surgery contributed to Virchow’s triad in this patient because endothelial injury made the patient prone to embolic events (7–9).

The patient we report was young, was not critically ill or septic, and had no evidence of disseminated intravascular coagulation. Alteration in coagulation pathways during pregnancy increases the risk for embolic events. The risk in the immediate postpartum period is particularly high. Venous embolism is an important cause of maternal illness and death (7).

CTA or ultrasonography for deep vein thrombosis may be important for COVID-19–positive pregnant or postpartum patients who have signs or symptoms of possible venous embolism, given their potentially heightened risk. In this patient population, with an already elevated risk for venous embolism, physicians should be aware of the potential for concurrent mild COVID-19 and acute pulmonary embolism.

Acknowledgments
We thank Shiraz University of Medical Sciences and the Center for Development of Clinical Research of Nemazee Hospital and Nasrin Shokrpour for editorial assistance.
About the Author
Dr. Khodamoradi is an internal medicine resident in Shiraz University of Medical Sciences, Shiraz, Iran. Her primary research interests focus on internal medicine, gastroenterology, rheumatology, and cardiology.

References
1. Khodamoradi Z, Moghadami M, Lotfi M. Co-infection of coronavirus disease 2019 and influenza A: a report from Iran. Arch Iran Med. 2020;23:239–43. https://doi.org/10.34172/aim.2020.04
2. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–9. https://doi.org/10.1111/jth.14817
3. Ng KH, Wu AK, Cheng VC, Tang BS, Chan CY, Yung CY, et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J. 2005;81:e3. https://doi.org/10.1136/pgmj.2004.030049
4. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020 Mar 30;ehaa254; Epub ahead of print. https://doi.org/10.1093/eurheartj/ehaa254
5. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology. Cardiothoracic Imaging. 2020;2:e200067. https://doi.org/10.1148/ryct.2020200067
6. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e1–17. https://doi.org/10.1056/NEJMoa2007575
7. Clinton CM, Kuller JA, James AH. Prevention of postpartum venous thromboembolism. Obstet Gynecol Surv. 2019;74:601–6. https://doi.org/10.1097/OGX.0000000000000714
8. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 196: thromboembolism in pregnancy. Obstet Gynecol. 2018;132:e1–17. https://doi.org/10.1097/AOG.0000000000002706
9. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44. https://doi.org/10.1016/j.thromres.2016.11.007

Address for correspondence: Shahrokh Sadeghi Boogar, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; email: sadeghi_sh@sums.ac.ir

Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19

Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent Robriquet, Sophie Six, Caroline Loiez, Frédéric Wallet

Author affiliations: Centre Hospitalier Universitaire Lille, Lille, France (C. Duployez, R. Le Guern, C. Tinez, A.-L. Lejeune, L. Robriquet, S. Six, C. Loiez, F. Wallet); University of Lille (C. Duployez, R. Le Guern, A.-L. Lejeune)

DOI: https://doi.org/10.3201/eid2608.201413

Panton-Valentine leukocidin (PVL) is a cytotoxin produced by some strains of Staphylococcus aureus. These strains are responsible for primary skin infections and necrotizing pneumonia. This rare entity is mainly described in young immunocompetent patients with an influenza-like prodrome and has a high case-fatality rate (1,2). We report a case of necrotizing pneumonia induced by PVL-secreting methicillin-susceptible S. aureus in a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and who had coronavirus disease (COVID-19).

In March 2020, during the SARS-CoV-2 outbreak in France, a man in his 30’s who had no underlying conditions came to an emergency department because of fever, cough, and blood-streaked sputum that developed for 3 days. A diagnosis of pleuropneumonia was made, and antimicrobial therapy was initiated with cefotaxime plus metronidazole. Test results for Streptococcus pneumoniae and Legionella pneumophila serotype 1 urinary antigens were negative. A reverse transcription PCR specific for respiratory viruses also showed negative results.

The next day, further respiratory deterioration required transfer of the patient to an intensive care unit (ICU) for intubation, mechanical ventilation, and inotropic support. Spiramycin was added to the previous drug regimen. Chest computed tomography showed a parenchymal consolidation of the left